Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Statins and running: new study to reveal hidden effects on endurance athletes

NCT ID NCT07401017

Knowledge-focused Sponsor: Taipei Medical University WanFang Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the cholesterol-lowering drug rosuvastatin affects fitness and muscle symptoms in people who run long distances at least three times a week. Researchers will compare runners taking rosuvastatin to those not taking it over three months, measuring changes in oxygen use and muscle discomfort. The goal is to understand if this statin interferes with endurance training or increases muscle problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Meets clinical criteria for statin therapy, including at least one of the following: * Family history of hyperlipidemia. * LDL-C ≥ 160 mg/dL. * 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk ≥ 7.5% * Diabetes mellitus with LDL-C ≥ 70 mg/dL. * Determined by a clinician to require lipid-lowering therapy. * Currently using or eligible to initiate rosuvastatin therapy. * Performs long-distance running at least 3 times per week and is willing to maintain regular training for 3 months. * Able and willing to undergo cardiopulmonary exercise testing (CPET) and to record training data using a sports watch (for TRIMP calculation). * No known drug allergies and provides written informed consent after study explanation. Exclusion Criteria: * Known allergy or intolerance to statins or rosuvastatin. * History of severe statin-related adverse events, including rhabdomyolysis or marked creatine kinase (CK) elevation. * Liver dysfunction with AST or ALT \> 3× upper limit of normal. * Moderate to severe renal impairment (eGFR \< 30 mL/min/1.73 m²). * Current lower-limb pain, tendon injury, or other conditions that prevent running training. * Not suitable for maximal cardiopulmonary exercise testing (CPET), such as unstable angina, uncontrolled hypertension, or recent cardiovascular events. * Pregnant or breastfeeding. * Inability to comply with study procedures, including use of a sports watch, regular follow-up visits, or maintaining running training.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder statin toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia Endurance training Long distance running Statin-associated muscle symptoms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taipei medical university

    Taipei, 116, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.